Curis, cancer, Life Sciences

Curis Begins Phase 1 Trial of Anti-Tumor Drug

Ryan McBride 8/26/08

Drug developer Curis (NASDAQ:CRIS), of Cambridge, MA, reported today that it has begun a Phase 1 clinical trial of an anti-cancer small molecule, dubbed CUDC-101. The experimental drug is designed to inhibit tumor cell growth and survival, and 18 to 40 patients are expected to enroll in the clinical trial.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.